Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[212Pb]VMT-α-NET in Advanced SSTR2 Positive Tumors
NCT05636618Phase 2Recruiting
- Sponsor
- Perspective Therapeutics, Inc.
- Start
- Sep 2023
- Primary completion
- Nov 2029
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of VMT-α-NET in Neuroendocrine Neoplasm (NEN), meningioma, pheochromocytoma, Paraganglioma (PGL), sponsored by Perspective Therapeutics, Inc.. Started Sep 2023; status: recruiting.
02
Drugs
VMT-α-NET
03
Conditions
Neuroendocrine Neoplasm (NEN)meningiomapheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05636618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636618.